Study suggests patients on anti-CD20 treatment able to mount potent T-cell responses following mRNA COVID-19 vaccination
Patients on anti-CD20 treatment are able to mount potent T-cell responses to mRNA coronavirus disease 2019 (COVID-19) vaccines, despite impaired humoral responses, according to a study published in Clinical Infectious Diseases. For the study, Natacha Madelon, University of Geneva, Geneva, Switzerland, and colleagues assessed humoral and T-cell responses in 37 patients treated with either ocrelizumab for multiple sclerosis (MS; n = 26) or rituximab for rheumatic diseases (n = 11) compared to 22 age-matched immunocompetent individuals after completion of 2 doses of mRNA-based COVID-19 vaccine...
EMA recommends approval of Comirnaty COVID-19 vaccine for children aged 5 to 11
The European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Us...
Neonatal acute kidney injury: a case-based approach
Neonatal acute kidney injury (AKI) is increasingly recognized as a common complication in critically
